Benta Strengthens Its European Presence with the Acquisition of the Italian CDMO NerPharMa in Milan
Milan, Italy, 18 February 2026 Benta has announced the acquisition of NerPharMa, a pharmaceutical manufacturing company located in Milan, Italy, from NMS Group. The acquisition marks a significant step in strengthening Benta’s European industrial platform and...
Nerviano Medical Sciences announces NMPA Clearance of IND for PARP7-Selective Inhibitor Atamparib in Promising New Therapeutic Setting
NERVIANO, Italy, BOSTON, Mass., SHANGHAI, China, 12 January 2026 – NMS Group (NMS), a global leader in oncological innovation, today announced that the China’s National Medical Products Administration (NMPA) has granted approval to the Investigational New Drug (IND) application for its first-in-class, orally bioavailable PARP7-selective inhibitor, atamparib, enabling its clinical studies in patients with advanced solid tumors.
Nerviano Medical Sciences (NMS) China Joins Roche Accelerator to Advance Oncology Innovation
Nerviano (Milan), Italy – Shanghai, China 17 November 2025 — Nerviano Medical Sciences (NMS), a clinical-stage biopharmaceutical company focused on oncology innovation, today announced that its subsidiary, Nerviano Medical Sciences (Shanghai) Co., Ltd. (NMS China), has officially joined the Roche Accelerator.
Nerviano Medical Sciences presented data on novel payload linkers for ADC conjugation at the World ADC Summit 2025
Nerviano (Milan), Italy, 7 November 2025 – Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A. and a clinical-stage biotech company discovering and developing innovative therapies for the treatment of cancer, presented its poster at the World ADC...
Nerviano Medical Sciences Srl Announces Participation in BIO-Europe 2025
Nerviano Medical Sciences Srl is excited to announce its participation in BIO-Europe 2025, one of the premier partnering conferences for the global biotechnology and pharmaceutical industry. The event, taking place in Vienna, Austria, November 3–5, 2025, brings...
NMS ADC poster and presentation – Novel Cytotoxin and Targeted Payload Platforms at Festival of Biologics
Nerviano Medical Sciences (NMS) ADC Business Unit Portfolio Head, Rosita Lupi, delivered an oral presentation at the Festival of Biologics in Basel (30/09/2025): “Reinventing Cytotoxins and Targeted Molecules as Next-Generation Payloads for ADCs.” The session was very...
Nerviano Medical Sciences Srl Launches China Subsidiary to Advance Oncology Pipeline and ADC Portfolio
NMS announced today the expansion of its presence in Asia with the establishment of Nerviano Medical Sciences (Shanghai) Ltd.
Accelera Appoints Silvia Guionaud, PhD, DECVP, as Chief Executive Officer
NERVIANO, Italy, 24 July 2025 — Accelera, a global leader in preclinical in vivo toxicology and contract research services, today announced the appointment of Dr. Silvia Guionaud, PhD, DECVP, as Chief Executive Officer, effective immediately.
BioNerviano Srl Appoints Serena Alvino as Chief Executive Officer
NERVIANO, Italy, 28 July 2025 — BioNerviano (BioN), a company provides services to the community domiciled in Nerviano Bio-Park, today announced the appointment of Serena Alvino, MBA, CIPP/E, as Chief Executive Officer, effective immediately.
NerPharMa Appoints Serena Alvino as Chief Executive Officer
NERVIANO, Italy, 28 July 2025 — NerPharMa (NPM), a renowned Contract Development and Manufacturing Organization (CDMO) specializing in oncology and in immunology, today announced the appointment of Serena Alvino, MBA, CIPP/E, as its new Chief Executive Officer, effective immediately.
Our Archive
Welcome and Check out our new motion picture!